AMASS Brands invests $1.435M in Afterdream via SAFE at $7.5M cap
What's the deal? Nasdaq-listed AMASS BrandsDealroom has a profile for this one. Try Dealroom → has invested $1,435,000 in startup AfterdreamDealroom has a profile for this one. Try Dealroom → through a Simple Agreement for Future Equity (SAFE).
The deal carries a post-money valuation cap of $7,500,000, according to a Form 8-K filing dated June 23, 2026. The SAFE converts into preferred stock upon an equity financing, liquidity event, or dissolution.
Why now? AMASS Brands also executed a First Amendment to the agreement, confirming the $7.5 million cap and all other terms remain unchanged.
The investor is an emerging growth company under the Securities Act and has not opted into the extended transition period for new accounting standards.
What could go wrong? Conversion of the SAFE could dilute existing shareholders, especially if Afterdream raises later rounds at lower valuations or expands its option pool.
The SAFE confers no voting rights until conversion. The investor must remain accredited under Rule 501 of Regulation D; if not, AMASS Brands may void the deal and reclaim its money.
On conversion, the SAFE prices at the lower of the $7.5 million cap or the price new investors pay. In a liquidity or dissolution event, the holder takes the greater of its $1,435,000 or the converted value.
The signal: AMASS Brands, itself a botanicals and spirits company, is backing Afterdream's microdosed cannabis beverage — a corporate bet that sits squarely within its own consumer category. The move underscores how strategic investors are using SAFEs to take early stakes in adjacent product lines while deferring valuation discussions to a future round.
Image credit: Generated with Gemini
